Merck's Q4 earnings call revealed a strong performance, with the company achieving a 2% top-line growth and 10% bottom-line growth, driven by broad strength across its in-line portfolio. The company's guidance for 2012 indicates that it expects to maintain its revenue at or near 2011 levels on a constant currency basis, despite headwinds such as the U.S. SINGULAIR patent expiration and annualization of the J&J settlement. Management's tone was optimistic, highlighting the company's ability to drive growth through its key products, emerging markets, and pipeline opportunities. The company's focus on cost management and productivity gains is expected to continue, with a goal of delivering a leveraged P&L. Overall, the call suggests that Merck is well-positioned for long-term success, with a strong pipeline and a diversified portfolio. However, the stock may face short-term pressure due to the tempered guidance and uncertainties around key products. 
[1]